Placebo News and Research

RSS

LEO Pharma reports encouraging data from PSO-FAST clinical trial of Enstilar for psoriasis treatment

LEO Pharma A/S today announced that new data being presented at the 23rd World Congress of Dermatology shows aerosol foam Enstilar® (calcipotriol/betamethasone dipropionate 50 micrograms/g / 0,5 mg/g), the Company's dual-action investigational aerosol foam for the treatment of psoriasis vulgaris, provided rapid itch relief and improvements in itch-related sleep loss for patients suffering from psoriasis.

10 Jun 2015

INS announces winners of inaugural best abstract competition at 12th World Congress

The International Neuromodulation Society (INS) announced winners today of its inaugural best abstract competition at the 12th World Congress in Montreal.

10 Jun 2015

Combining lifestyle modification with metformin could help women manage polycystic ovary syndrome

A systematic review publishing today in the journal Human Reproduction Update has found that women who suffer from polycystic ovary syndrome (PCOS) could manage some of the symptoms by combining a change in lifestyle with taking the drug metformin.

10 Jun 2015

CHIMES-E study: NeuroAiD provides long-term benefits to patients after ischemic stroke

Moleac is pleased to announce the release of the CHIMES-E study results published online in the journal Cerebrovascular Diseases. It provides convincing data on NeuroAiD which confirm its persistent long-term benefits on patients' recovery after an ischemic stroke.

10 Jun 2015

Danish nasal filter prevents pollen inhalation, reduces symptoms of hay fever

Getting through the pollen season can now become easier for some of the approximately 500 million people worldwide who suffer from sneezing and a runny nose, watery eyes and drowsiness during the allergy season (seasonal allergic rhinitis).

10 Jun 2015

Phase 2 study of AR101 meets primary endpoint in patients with peanut allergy

Aimmune Therapeutics, Inc., a privately held biopharmaceutical company developing desensitization treatments for food allergies, announced today that a Phase 2 study (ARC001) evaluating the company's lead investigational product, AR101 for the treatment of peanut allergy, met its primary endpoint and additional endpoint of desensitizing patients to cumulative amounts of peanut protein of 443 mg and 1,043 mg, respectively.

10 Jun 2015

New clinical trial compares outcomes of vitamin D supplementation on pediatric burn patients

Deficiency of vitamin D is a common problem for patients with severe burn injuries and can lead to further health compromise. However, there are no evidence-based guidelines for vitamin D replenishment in such patients.

10 Jun 2015

Stemedica receives FDA's IND approval for itMSC Phase IIa clinical trial to treat Alzheimer's disease

Stemedica Cell Technologies, Inc. received the FDA's investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with mild to moderate dementia due to Alzheimer's disease (AD), the sixth leading cause of death in the United States.

9 Jun 2015

Study shows how GLP-1 receptor agonists modify the brain's response to food

Gut hormone-based medications used to treat diabetes, such as GLP-1 receptor agonists, have also been shown to reduce body weight. Researchers have been working to understand how. This study, presented today at the American Diabetes Association's 75th Scientific Sessions, sheds light on how GLP-1 receptor agonists alter the brain's response to food, possibly reducing cravings and increasing satisfaction while eating.

9 Jun 2015

Glucose-control drug sitagliptin does not raise risk of cardiovascular events

A clinical trial of the glucose-control drug sitagliptin among patients with type 2 diabetes and established cardiovascular disease has found it did not raise the risk of major adverse cardiovascular events.

9 Jun 2015

Lactobacillus reuteri may reduce risk of necrotizing enterocolitis in premature infants

A new study finds that supplementing enteral nutrition with Lactobacillus reuteri (L. reuteri) DSM 17938 as a probiotic may reduce the risk of necrotizing enterocolitis (NEC) in premature infants.

9 Jun 2015

Ibrutinib shows promise in CLL/SLL

The addition of ibrutinib to bendamustine and rituximab significantly prolongs progression-free survival in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma, according to the HELIOS trial.

8 Jun 2015

Sanofi announces results from Phase IIIb ELIXA study of Lyxumia in adults with diabetes and high CV risk

Sanofi announced today the presentation of full results of the Phase IIIb ELIXA study, which was designed to assess the cardiovascular (CV) safety of Lyxumia (lixisenatide) in adults with type 2 diabetes and high CV risk.

8 Jun 2015

Jazz enrolls first patients in JZP-110 Phase 3 study for treatment of EDS in patients with narcolepsy or OSA

Jazz Pharmaceuticals plc announced today that the first patients have been enrolled in a Phase 3 clinical development program evaluating the safety and efficacy of its investigational drug candidate, JZP-110, as a wake-promoting agent in the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy or with obstructive sleep apnea (OSA).

8 Jun 2015

Results from Intarcia's two phase 3 clinical trials of ITCA 650 to be presented at ADA's Scientific Session

Intarcia Therapeutics, Inc. today announced the presentation of results from its first two phase 3 clinical trials (FREEDOM-1 and FREEDOM-1 HBL) of its late-stage investigational candidate ITCA 650 (exenatide delivered continuously via a small matchstick-size subcutaneous osmotic mini-pump just once or twice yearly) at the 75th Scientific Sessions of the American Diabetes Association.

8 Jun 2015

DalCor, MHI partner to conduct Phase III clinical trial of investigational cardiovascular drug

DalCor Pharmaceuticals and the Montreal Heart Institute announced today a collaboration in principle to conduct an international Phase III clinical trial which could result in a major clinical advance in cardiovascular personalised medicine.

8 Jun 2015

Braeburn reports positive topline results from Probuphine Phase 3 study for treatment of opioid addiction

Braeburn Pharmaceuticals, an Apple Tree Partners company, today reported positive topline results from the Phase 3 double-blind, double-dummy clinical study of Probuphine, the investigational subdermal implant containing buprenorphine HCl for the long-term maintenance treatment of opioid addiction.

8 Jun 2015

Nuvo obtains Health Canada approval to conduct WF10 Phase 2 trial for treatment of allergic rhinitis

Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced it has received Health Canada approval to conduct a new Phase 2 clinical trial (the 2015 WF10 Trial) to assess WF10 for the treatment of allergic rhinitis.

8 Jun 2015

Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

Results from a new study of Japanese patients with type 2 diabetes showed once-weekly Trulicity 0.75 mg provided greater hemoglobin A1c (A1C) reduction compared to once-daily Victoza 0.9 mg after 52 weeks of treatment. Eli Lilly and Company will present these data at the 75th American Diabetes Association Scientific Sessions in Boston.

7 Jun 2015

PALOMA3 supports palbociclib use in advanced breast cancer

Advanced breast cancer patients who have failed prior endocrine treatment may receive a progression-free survival benefit if palbociclib is added to fulvestrant, a phase III trial indicates.

5 Jun 2015

Placebo News and Research

LEO Pharma reports encouraging data from PSO-FAST clinical trial of Enstilar for psoriasis treatment

INS announces winners of inaugural best abstract competition at 12th World Congress

Combining lifestyle modification with metformin could help women manage polycystic ovary syndrome

CHIMES-E study: NeuroAiD provides long-term benefits to patients after ischemic stroke

Danish nasal filter prevents pollen inhalation, reduces symptoms of hay fever

Phase 2 study of AR101 meets primary endpoint in patients with peanut allergy

New clinical trial compares outcomes of vitamin D supplementation on pediatric burn patients

Stemedica receives FDA's IND approval for itMSC Phase IIa clinical trial to treat Alzheimer's disease

Study shows how GLP-1 receptor agonists modify the brain's response to food

Glucose-control drug sitagliptin does not raise risk of cardiovascular events

Lactobacillus reuteri may reduce risk of necrotizing enterocolitis in premature infants

Ibrutinib shows promise in CLL/SLL

Sanofi announces results from Phase IIIb ELIXA study of Lyxumia in adults with diabetes and high CV risk

Jazz enrolls first patients in JZP-110 Phase 3 study for treatment of EDS in patients with narcolepsy or OSA

Results from Intarcia's two phase 3 clinical trials of ITCA 650 to be presented at ADA's Scientific Session

DalCor, MHI partner to conduct Phase III clinical trial of investigational cardiovascular drug

Braeburn reports positive topline results from Probuphine Phase 3 study for treatment of opioid addiction

Nuvo obtains Health Canada approval to conduct WF10 Phase 2 trial for treatment of allergic rhinitis

Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

PALOMA3 supports palbociclib use in advanced breast cancer

Industry Focus eBook - Cell biology (5th edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News